Mouse Anti-CYP4F3 Recombinant Antibody (4E11) (CBMAB-C6838-LY)

Mouse

Human

4E11

IgG2b, κ

ELISA, WB

Partial recombinant corresponding to aa100-198 from human CYP4F3 (NP_000887) with GST tag. MW of the GST tag alone is 26kD

Human

IgG2b, κ

Monoclonal

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Liquid

> 95% Purity determined by SDS-PAGE.

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

cytochrome P450, family 4, subfamily F, polypeptide 3

CYP4F3 (Cytochrome P450 Family 4 Subfamily F Member 3) is a Protein Coding gene. Diseases associated with CYP4F3 include Inflammatory Bowel Disease 6. Among its related pathways are Arachidonic acid metabolism and Metabolism. Gene Ontology (GO) annotations related to this gene include iron ion binding and oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen.
An important paralog of this gene is CYP4F2.

Cytochrome P450 Family 4 Subfamily F Member 3; Cytochrome P450, Subfamily IVF, Polypeptide 3 (Leukotriene B4 Omega Hydroxylase); Cytochrome P450, Family 4, Subfamily F, Polypeptide 3; 20-Hydroxyeicosatetraenoic Acid Synthase; Leukotriene-B(4) Omega-Hydroxylase 2; Leukotriene-B(4) 20-Monooxygenase 2; Cytochrome P450-LTB-Omega; Cytochrome P450 4F3; 20-HETE Synthase; CYPIVF3; LTB4H;

A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15145985, PubMed:16547005, PubMed:16820285, PubMed:18182499, PubMed:18065749, PubMed:18577768).

Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:9675028).

May play a role in inactivation of proinflammatory and anti-inflammatory oxylipins during the resolution of inflammation (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15145985, PubMed:15364545, PubMed:16547005, PubMed:16820285, PubMed:18182499, PubMed:18065749, PubMed:18577768).

Isoform CYP4F3A:
Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of oxylipins in myeloid cells, displaying higher affinity for arachidonate metabolite leukotriene B4 (LTB4) (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15364545).

Inactivates LTB4 via three successive oxidative transformations to 20-hydroxy-LTB4, then to 20-oxo-LTB4 and to 20-carboxy-LTB4 (PubMed:9675028).

Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985).

Omega-hydroxylates monohydroxy polyunsaturated fatty acids (PUFAs), including hydroxyeicosatetraenoates (HETEs) and hydroxyeicosapentaenoates (HEPEs), to dihydroxy compounds (PubMed:15364545, PubMed:9675028).

Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acid, thereby initiating chain shortening (PubMed:18182499).

Has low hydroxylase activity toward PUFAs (PubMed:18577768, PubMed:11461919).

Isoform CYP4F3B:
Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of polyunsaturated fatty acids (PUFAs) (PubMed:11461919, PubMed:16820285, PubMed:18577768).

Participates in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:11461919, PubMed:16820285, PubMed:18577768).

Has high omega-hydroxylase activity toward other PUFAs, including eicosatrienoic acid (ETA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (PubMed:16820285, PubMed:18577768).

Can also catalyze the oxidation of the penultimate carbon (omega-1 oxidation) of PUFAs with lower efficiency (PubMed:18577768).

Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid and hexacosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acids, thereby initiating chain shortening (PubMed:16547005, PubMed:18182499).

Omega-hydroxylates long-chain 3-hydroxy fatty acids, likely initiating the oxidative conversion to the corresponding 3-hydroxydicarboxylic fatty acids (PubMed:18065749).

Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985).

Arachidonic acid metabolic process Source: GO_Central
Icosanoid metabolic process Source: Reactome
Leukotriene B4 catabolic process Source: GO_Central
Leukotriene metabolic process Source: Reactome
Menaquinone catabolic process Source: GO_Central
Phylloquinone catabolic process Source: GO_Central
Vitamin K catabolic process Source: GO_Central

Endoplasmic reticulum membrane; Microsome membrane

Helical: 11-31